Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642878 | 0.86 | KDR (0.48) | ALDH1A1MAPT | |
| SCHEMBL22737611 | 0.85 | GCK (0.56) | ALDH1A1GRM5 | |
| SCHEMBL177723 | 0.85 | KDR (0.57) | — | |
| SCHEMBL24310884 | 0.84 | KDR (0.48) | ALDH1A1MAPTGRM5 | |
| SCHEMBL177837 | 0.84 | MAOB (0.50) | ALDH1A1MAOBMAPTGRM5 | |
| SCHEMBL3409437 | 0.84 | MAOB (0.54) | ALDH1A1MAOBMAPTGRM5 | |
| SCHEMBL13408257 | 0.81 | MAPT (0.51) | ALDH1A1MAOBMAPTCYP3A4 | |
| SCHEMBL1336313 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTCYP3A4 | |
| SCHEMBL3549305 | 0.79 | MET (0.47) | — | |
| Hydrochloric Acid SCHEMBL31345624 | 0.79 | ALDH1A1 (0.49) | ALDH1A1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| EP-1608639-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1603879-A2 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | disclosed |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-18 | — | — | US | disclosed |
| WO-2004078128-A2 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078748-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | CCNC, UACA, SLC14A1 | ALDH1A1 1861/4885MAOB 2068/4885MAPT 1011/4885 |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | CDK4, MKI67, TP53 | ALDH1A1 1298/4885MAOB 1370/4885MAPT 1522/4885 |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | CDK4, MKI67, TP53 | ALDH1A1 1298/4885MAOB 1370/4885MAPT 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.